Initiating Free Research Reports on Quest Diagnostics and Three Other Medical Research Equities

Stock Research Monitor: PKI, PRAH, and PRPO

LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on DGX sign up now at www.wallstequities.com/registration. On Monday, benchmark US indices were in bearish colors as the NASDAQ Composite closed the trading session down 2.09%; the Dow Jones Industrial Average edged 1.33% lower; and the S&P 500 was down 1.37%. US markets made broad based losses with seven out of nine sectors finishing the day in red. Pre-market today, WallStEquities.com reviews these four Medical Laboratories & Research stocks: PerkinElmer Inc. (NYSE: PKI), PRA Health Sciences Inc. (NASDAQ: PRAH), Precipio Inc. (NASDAQ: PRPO), and Quest Diagnostics Inc. (NYSE: DGX). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

PerkinElmer

Waltham, Massachusetts headquartered PerkinElmer Inc.’s stock finished Monday’s session 2.00% lower at $72.87. A total volume of 573,053 shares was traded. The Company’s shares have advanced 6.46% in the last twelve months. The stock is trading below its 50-day moving average by 3.22%. Furthermore, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide, have a Relative Strength Index (RSI) of 33.39. Get the full research report on PKI for free by clicking below at:

www.wallstequities.com/registration/?symbol=PKI

PRA Health Sciences

Shares in Raleigh, North Carolina headquartered PRA Health Sciences Inc. ended at $94.24, down 1.03% from the last trading session. The stock recorded a trading volume of 648,653 shares. The Company’s shares have gained 16.50% in the last month and 25.02% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 9.67% and 10.94%, respectively. Moreover, shares of the Company, which provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide, have an RSI of 67.04. Gain free access to the research report on PRAH at:

www.wallstequities.com/registration/?symbol=PRAH

Precipio

New Haven, Connecticut-based Precipio Inc.’s stock ended yesterday’s session 7.84% lower at $0.39 with a total trading volume of 602,660 shares. The stock is trading below its 50-day moving average by 13.27%. Additionally, shares of Precipio, which provides platform to eradicate the problem of misdiagnosis within academic institutions, have an RSI of 34.80. Signing up today on Wall St. Equities will give you access to the latest report on PRPO at:

www.wallstequities.com/registration/?symbol=PRPO

Quest Diagnostics

On Monday, shares in Secaucus, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 1.25 million shares, which was above their three months average volume of 971.85 thousand shares. The stock finished the day 0.98% higher at $113.14. The Company’s shares have advanced 12.14% in the last month and 12.67% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 8.33% and 12.81%, respectively. Furthermore, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 71.42.

On June 25th, 2018, research firm Barclays upgraded the Company’s stock rating from ‘Equal Weight’ to ‘Overweight’ while revising its previous target price from $120 a share to $130 a share. Register now for today’s free coverage on DGX at:

www.wallstequities.com/registration/?symbol=DGX

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 503718